AASLD HCC - Hepatitis - Clinical Care Options

Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective

Review the mechanism of action for immune checkpoint inhibitors, the rationale and data supporting their use in HCC, and key issues and controversies around moving this new class of agents into the clinic from the live satellite symposium at AASLD 2016.

Source: Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective

Date Posted: 12/5/2016
Clinical Development of Immune Checkpoint Inhibitors in HCC

In this downloadable slideset, Ghassan K. Abou-Alfa, MD, MBA, reviews the rationale for immunotherapy in hepatocellular carcinoma, as well as the emerging and ongoing data supporting the use of immune checkpoint inhibitors to treat patients with HCC, from a satellite symposium at the 2016 American Association for the Study of Liver Diseases Annual Meeting.

Source: Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective

Date Posted: 11/14/2016
Overview of Immunotherapy for Cancer

In this downloadable slideset, Osama E. Rahma, MD, provides an overview of immunotherapy in cancer, including tumor immunology and evolution of immune checkpoint inhibitors in solid tumors, from a satellite symposium at the 2016 American Association for the Study of Liver Diseases Annual Meeting.

Source: Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective

Date Posted: 11/11/2016
Key Issues and Current Controversies in Moving Immunotherapy Into the Clinic for Patients With Advanced HCC

In this downloadable slideset, Andrew X. Zhu, MD, PhD, FACP, reviews the key issues around integrating immune checkpoint inhibitors into the clinic for patients with HCC, including management of immune-related adverse events, predictors of response, resistance, and safety concerns, from a satellite symposium at the 2016 American Association for the Study of Liver Diseases Annual Meeting.

Source: Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective

Date Posted: 11/11/2016

Other Sites

Topics

Educational Formats

Program Resources

User Resources

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective
Table of Contents AASLD HCC Slides • Immunotherapy for Cancer • Immune CPIs in HCC • Key Issues with Immunotherapy in HCC AASLD HCC Webcast • HCC Immunotherapy	Program Overview Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective Gain expert perspective on optimal use of promising new checkpoint inhibitors for patients with hepatocellular carcinoma through 3 downloadable PowerPoint slidesets and an on-demand Webcast from the live symposium presented at the 2016 annual meeting of the AASLD in Boston, Massachusetts. Featured content Overview of Immunotherapy for Cancer In this downloadable slideset, Osama E. Rahma, MD, provides an overview of immunotherapy in cancer, including tumor immunology and evolution of immune checkpoint inhibitors in solid tumors, from a satellite symposium at the 2016 American Association for the Study of Liver Diseases Annual Meeting. Date Posted: 11/11/2016 1 2 Latest Content 4 of 4 Shown Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective Review the mechanism of action for immune checkpoint inhibitors, the rationale and data supporting their use in HCC, and key issues and controversies around moving this new class of agents into the clinic from the live satellite symposium at AASLD 2016. Source: Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective Date Posted: 12/5/2016 Clinical Development of Immune Checkpoint Inhibitors in HCC In this downloadable slideset, Ghassan K. Abou-Alfa, MD, MBA, reviews the rationale for immunotherapy in hepatocellular carcinoma, as well as the emerging and ongoing data supporting the use of immune checkpoint inhibitors to treat patients with HCC, from a satellite symposium at the 2016 American Association for the Study of Liver Diseases Annual Meeting. Source: Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective Date Posted: 11/14/2016 Overview of Immunotherapy for Cancer In this downloadable slideset, Osama E. Rahma, MD, provides an overview of immunotherapy in cancer, including tumor immunology and evolution of immune checkpoint inhibitors in solid tumors, from a satellite symposium at the 2016 American Association for the Study of Liver Diseases Annual Meeting. Source: Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective Date Posted: 11/11/2016 Key Issues and Current Controversies in Moving Immunotherapy Into the Clinic for Patients With Advanced HCC In this downloadable slideset, Andrew X. Zhu, MD, PhD, FACP, reviews the key issues around integrating immune checkpoint inhibitors into the clinic for patients with HCC, including management of immune-related adverse events, predictors of response, resistance, and safety concerns, from a satellite symposium at the 2016 American Association for the Study of Liver Diseases Annual Meeting. Source: Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective Date Posted: 11/11/2016 4 of 4 Shown Show 0 More Loading...	Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC Contact Info Supported by an educational grant from Presented for attendees of the 67th AASLD Annual Meeting. This event/function is sponsored by Clinical Care Options, LLC and supported by Bristol-Myers Squibb. This is not an official function/event of the American Association for the Study of Liver Diseases

Table of Contents

Latest Content

Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective

Clinical Development of Immune Checkpoint Inhibitors in HCC

Overview of Immunotherapy for Cancer

Key Issues and Current Controversies in Moving Immunotherapy Into the Clinic for Patients With Advanced HCC